{"id":"https://openalex.org/W2266979115","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.8008","title":"Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673).","display_name":"Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673).","publication_year":2015,"publication_date":"2015-05-20","ids":{"openalex":"https://openalex.org/W2266979115","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.8008","mag":"2266979115"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2015.33.15_suppl.8008","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.8008","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2015.33.15_suppl.8008","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5087923582","display_name":"Sai\u2010Hong Ignatius Ou","orcid":"https://orcid.org/0000-0002-1764-4975","observed_orcids":["https://orcid.org/0000-0002-1764-4975"]},"institutions":[{"id":"https://openalex.org/I204250578","display_name":"University of California, Irvine","ror":"https://ror.org/04gyf1771","country_code":"US","type":"education","lineage":["https://openalex.org/I204250578"]},{"id":"https://openalex.org/I4390039238","display_name":"UC Irvine Chao Family Comprehensive Cancer Center","ror":"https://ror.org/05gzqy922","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I204250578","https://openalex.org/I4390039238"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sai-Hong Ignatius Ou","raw_affiliation_strings":["Chao Family Comp Cancer Ctr  UC Irvine Medcl Ctr, Orange, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chao Family Comp Cancer Ctr  UC Irvine Medcl Ctr, Orange, CA","institution_ids":["https://openalex.org/I204250578","https://openalex.org/I4390039238"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107869955","display_name":"Jin Seok Ahn","orcid":"https://orcid.org/0000-0002-2880-6730","observed_orcids":["https://orcid.org/0000-0002-2880-6730"]},"institutions":[{"id":"https://openalex.org/I2802194831","display_name":"Samsung Medical Center","ror":"https://ror.org/05a15z872","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I2250650973","https://openalex.org/I2802194831"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Jin Seok Ahn","raw_affiliation_strings":["Samsung Medical Center, Seoul, South Korea"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Samsung Medical Center, Seoul, South Korea","institution_ids":["https://openalex.org/I2802194831"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058658281","display_name":"Luigi De Petris","orcid":"https://orcid.org/0000-0001-8393-560X","observed_orcids":["https://orcid.org/0000-0001-8393-560X"]},"institutions":[{"id":"https://openalex.org/I1335113835","display_name":"Karolinska University Hospital","ror":"https://ror.org/00m8d6786","country_code":"SE","type":"healthcare","lineage":["https://openalex.org/I1335113835"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"Luigi De Petris","raw_affiliation_strings":["Karolinska University Hospital Solna, Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karolinska University Hospital Solna, Stockholm, Sweden","institution_ids":["https://openalex.org/I1335113835"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068824818","display_name":"Ramaswamy Govindan","orcid":"https://orcid.org/0000-0002-6964-9612","observed_orcids":["https://orcid.org/0000-0002-6964-9612"]},"institutions":[{"id":"https://openalex.org/I204465549","display_name":"Washington University in St. Louis","ror":"https://ror.org/01yc7t268","country_code":"US","type":"education","lineage":["https://openalex.org/I204465549"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ramaswamy Govindan","raw_affiliation_strings":["Washington University School of Medicine, St. Louis, MO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Washington University School of Medicine, St. Louis, MO","institution_ids":["https://openalex.org/I204465549"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055074037","display_name":"James Chih\u2010Hsin Yang","orcid":"https://orcid.org/0000-0002-5586-5138","observed_orcids":["https://orcid.org/0000-0002-5586-5138"]},"institutions":[{"id":"https://openalex.org/I16733864","display_name":"National Taiwan University","ror":"https://ror.org/05bqach95","country_code":"TW","type":"education","lineage":["https://openalex.org/I16733864"]}],"countries":["TW"],"is_corresponding":false,"raw_author_name":"James Chih-Hsin Yang","raw_affiliation_strings":["National Taiwan University, Taipei, Taiwan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Taiwan University, Taipei, Taiwan","institution_ids":["https://openalex.org/I16733864"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051086683","display_name":"Brett G.M. Hughes","orcid":"https://orcid.org/0000-0002-1811-0537","observed_orcids":["https://orcid.org/0000-0002-1811-0537"]},"institutions":[{"id":"https://openalex.org/I4210125554","display_name":"Prince Charles Hospital","ror":"https://ror.org/02cetwy62","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I1302211766","https://openalex.org/I2801244131","https://openalex.org/I4210125554"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Brett Gordon Maxwell Hughes","raw_affiliation_strings":["The Prince Charles Hospital, Brisbane, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Prince Charles Hospital, Brisbane, Australia","institution_ids":["https://openalex.org/I4210125554"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040544006","display_name":"H. L\u00e9na","orcid":"https://orcid.org/0000-0002-4115-9400","observed_orcids":["https://orcid.org/0000-0002-4115-9400"]},"institutions":[{"id":"https://openalex.org/I4210124872","display_name":"H\u00f4pital Pontchaillou","ror":"https://ror.org/02r25sw81","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210124872","https://openalex.org/I4210155724"]},{"id":"https://openalex.org/I4210155724","display_name":"Centre Hospitalier Universitaire de Rennes","ror":"https://ror.org/05qec5a53","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210155724"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Herv\u00e9 Lena","raw_affiliation_strings":["Centre Hospitalier Universitaire, Hopital Pontchaillou, Rennes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centre Hospitalier Universitaire, Hopital Pontchaillou, Rennes, France","institution_ids":["https://openalex.org/I4210124872","https://openalex.org/I4210155724"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030455508","display_name":"Denis Moro\u2010Sibilot","orcid":"https://orcid.org/0000-0001-6776-8610","observed_orcids":["https://orcid.org/0000-0001-6776-8610"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210162920","display_name":"H\u00f4pital Albert Michallon","ror":"https://ror.org/05kfvx519","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I2800555055","https://openalex.org/I4210162920"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Denis Moro-Sibilot","raw_affiliation_strings":["Thoracic Oncology Unit Teaching Hospital A Michallon, INSERM U823, Grenoble, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Thoracic Oncology Unit Teaching Hospital A Michallon, INSERM U823, Grenoble, France","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I4210162920"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026639715","display_name":"Alessandra Bearz","orcid":"https://orcid.org/0000-0003-1020-2338","observed_orcids":["https://orcid.org/0000-0003-1020-2338"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alessandra Bearz","raw_affiliation_strings":["IRCCS Centro Rif Oncologico, Pordenone, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"IRCCS Centro Rif Oncologico, Pordenone, Italy","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040541281","display_name":"Santiago Viteri","orcid":"https://orcid.org/0000-0002-7572-1123","observed_orcids":["https://orcid.org/0000-0002-7572-1123"]},"institutions":[{"id":"https://openalex.org/I4210096255","display_name":"Hospital Universitario Dexeus","ror":"https://ror.org/00scfzf83","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210096255"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Santiago Viteri Ramirez","raw_affiliation_strings":["Quir\u00f3n Dexeus University Hospital, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Quir\u00f3n Dexeus University Hospital, Barcelona, Spain","institution_ids":["https://openalex.org/I4210096255"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111567764","display_name":"Tarek M. Mekhail","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210085997","display_name":"Florida Hospital Cancer Institute","ror":"https://ror.org/00aqz8k66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210085997"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tarek Mekhail","raw_affiliation_strings":["Florida Hospital Cancer Institute, Orlando, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Florida Hospital Cancer Institute, Orlando, FL","institution_ids":["https://openalex.org/I4210085997"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044613951","display_name":"Alexander I. Spira","orcid":"https://orcid.org/0000-0003-1303-0447","observed_orcids":["https://orcid.org/0000-0003-1303-0447"]},"institutions":[{"id":"https://openalex.org/I4210122908","display_name":"Virginia Cancer Specialists","ror":"https://ror.org/03tbabt10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210122908"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexander I. Spira","raw_affiliation_strings":["Virginia Cancer Specialists Research Institute, US Oncology Research, Fairfax, VA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Virginia Cancer Specialists Research Institute, US Oncology Research, Fairfax, VA","institution_ids":["https://openalex.org/I4210122908"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083698345","display_name":"Ali Hassan Zeaiter","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Ali Hassan Zeaiter","raw_affiliation_strings":["F-Hoffmann-La Roche Ltd, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F-Hoffmann-La Roche Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062173452","display_name":"Walter Bordogna","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Walter Bordogna","raw_affiliation_strings":["F.Hoffmann-La Roche, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F.Hoffmann-La Roche, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113033858","display_name":"Bogdana I Balas","orcid":"https://orcid.org/0000-0003-0999-6185","observed_orcids":["https://orcid.org/0000-0003-0999-6185"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Bogdana Balas","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110985671","display_name":"Sophie Golding","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Sophie Golding","raw_affiliation_strings":["F. Hoffman La Roche Ltd, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffman La Roche Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002362734","display_name":"Peter N. Morcos","orcid":"https://orcid.org/0000-0001-9586-4095","observed_orcids":["https://orcid.org/0000-0001-9586-4095"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter N. Morcos","raw_affiliation_strings":["F. Hoffmann-La Roche, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche, New York, NY","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100638261","display_name":"Dong\u2010Wan Kim","orcid":"https://orcid.org/0000-0001-5124-7132","observed_orcids":["https://orcid.org/0000-0001-5124-7132"]},"institutions":[{"id":"https://openalex.org/I2802835388","display_name":"Seoul National University Hospital","ror":"https://ror.org/01z4nnt86","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I139264467","https://openalex.org/I2802835388"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Dong-Wan Kim","raw_affiliation_strings":["Seoul National University Hospital, Seoul, South Korea"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Seoul National University Hospital, Seoul, South Korea","institution_ids":["https://openalex.org/I2802835388"]}]}],"institutions":[],"countries_distinct_count":8,"institutions_distinct_count":16,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":31,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"33","issue":"15_suppl","first_page":"8008","last_page":"8008"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alectinib","display_name":"alectinib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/alk-positive-non-small-cell-lung-cancer","display_name":"ALK-positive non-small cell lung cancer","score":0.8349999785423279},{"id":"https://openalex.org/keywords/crizotinib-resistance","display_name":"crizotinib resistance","score":0.8479999899864197},{"id":"https://openalex.org/keywords/alk-inhibitors","display_name":"ALK inhibitors","score":0.7409999966621399},{"id":"https://openalex.org/keywords/central-nervous-system-metastases","display_name":"central nervous system metastasis","score":0.5260000228881836},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.7279999852180481},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7689999938011169},{"id":"https://openalex.org/keywords/cns-progression","display_name":"CNS progression","score":0.5049999952316284},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5519999861717224},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.6439999938011169},{"id":"https://openalex.org/keywords/alk-rearrangement","display_name":"ALK rearrangement","score":0.5389999747276306},{"id":"https://openalex.org/keywords/disease-control-rate","display_name":"disease control rate","score":0.5189999938011169},{"id":"https://openalex.org/keywords/duration-of-response","display_name":"duration of response","score":0.7329999804496765},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6370000243186951},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.5180000066757202}],"concepts":[{"id":"https://openalex.org/C2779422266","wikidata":"https://www.wikidata.org/wiki/Q5186964","display_name":"Crizotinib","level":4,"score":0.9722198247909546},{"id":"https://openalex.org/C2779220645","wikidata":"https://www.wikidata.org/wiki/Q21099132","display_name":"Alectinib","level":5,"score":0.9502334594726562},{"id":"https://openalex.org/C2778347629","wikidata":"https://www.wikidata.org/wiki/Q4652380","display_name":"ALK inhibitor","level":5,"score":0.8828533887863159},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8673553466796875},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.5695636868476868},{"id":"https://openalex.org/C2779177807","wikidata":"https://www.wikidata.org/wiki/Q3658562","display_name":"non-small cell lung cancer (NSCLC)","level":4,"score":0.5461344718933105},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5122069716453552},{"id":"https://openalex.org/C2779750558","wikidata":"https://www.wikidata.org/wiki/Q21011233","display_name":"Ceritinib","level":5,"score":0.48099860548973083},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48012399673461914},{"id":"https://openalex.org/C117643217","wikidata":"https://www.wikidata.org/wiki/Q17824987","display_name":"Anaplastic lymphoma kinase","level":4,"score":0.46139976382255554},{"id":"https://openalex.org/C3019800554","wikidata":"https://www.wikidata.org/wiki/Q3813242","display_name":"Open label","level":3,"score":0.44743460416793823},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.21403083205223083},{"id":"https://openalex.org/C2776232967","wikidata":"https://www.wikidata.org/wiki/Q6743514","display_name":"Malignant pleural effusion","level":3,"score":0.0},{"id":"https://openalex.org/C81729549","wikidata":"https://www.wikidata.org/wiki/Q4649475","display_name":"A549 cell","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2015.33.15_suppl.8008","doi":"https://doi.org/10.1200/jco.2015.33.15_suppl.8008","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2015.33.15_suppl.8008","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","score":0.8500000238418579,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2523104533","https://openalex.org/W2891185672","https://openalex.org/W2586673947","https://openalex.org/W2569631206","https://openalex.org/W2208535430","https://openalex.org/W2887526597","https://openalex.org/W2624982360","https://openalex.org/W2511937637","https://openalex.org/W2624310346","https://openalex.org/W2174368583"],"abstract_inverted_index":{"8008":[0],"Background:":[1],"The":[2,27],"ALK":[3,42,89],"inhibitor":[4,90],"crizotinib":[5,203,325],"is":[6,25],"approved":[7],"for":[8],"patients":[9,198,220],"(pts)":[10],"with":[11,178,199,221],"ALK-rearranged":[12],"(ALK+)":[13],"NSCLC,":[14],"but":[15],"most":[16,259,307],"pts":[17,47,55,137,177,252,301],"progress":[18],"within":[19],"a":[20,38,290],"year":[21],"and":[22,34,119,133,202,243,263,275,288,313,326],"CNS":[23,117,128,160,224,230,315],"progression":[24,129],"common.":[26],"NP28673":[28],"study":[29],"(NCT01801111)":[30],"investigated":[31],"the":[32,86,144,170],"efficacy":[33],"safety":[35],"of":[36,114,251,269,321],"alectinib,":[37],"highly":[39],"selective,":[40],"CNS-active":[41],"inhibitor,":[43],"in":[44,298],"ALK+":[45,64,299],"NSCLC":[46,65,300],"who":[48,302],"had":[49,154,158,253,303,308,314],"progressed":[50,304],"on":[51,305],"crizotinib.":[52],"Methods:":[53],"Eligible":[54],"(":[56],"\u2265":[57],"18":[58,145],"yrs;":[59,152],"locally":[60],"advanced":[61],"or":[62,82],"metastatic":[63],"[by":[66],"FDA-approved":[67],"FISH":[68],"test];":[69],"failed":[70,310],"on/intolerant":[71],"to":[72,279],"crizotinib)":[73],"received":[74],"alectinib":[75,323],"600mg":[76],"p.o.":[77],"BID":[78],"until":[79],"progression,":[80],"death":[81],"withdrawal.":[83],"Crizotinib":[84],"was":[85,94,166,184,192,208,214,232,285],"only":[87],"prior":[88,155,200,311],"permitted.":[91],"Primary":[92],"endpoint":[93],"objective":[95],"response":[96,115],"rate":[97,126],"(ORR)":[98],"by":[99,111,143,174],"independent":[100],"review":[101],"committee":[102],"(IRC)":[103],"using":[104],"RECIST":[105],"v1.1.":[106],"Secondary":[107],"endpoints":[108],"included":[109],"ORR":[110,118,183,207,231],"investigator;":[112],"duration":[113],"(DOR);":[116],"DOR;":[120],"progression-free":[121],"survival":[122],"(PFS);":[123],"disease":[124,180,225],"control":[125],"(DCR),":[127],"rate,":[130],"overall":[131],"survival,":[132],"safety.":[134],"Results:":[135],"138":[136],"from":[138],"16":[139],"countries":[140],"were":[141,281],"enrolled":[142],"Aug":[146],"2014":[147],"cut-off.":[148],"Median":[149,164],"age":[150],"52":[151],"80%":[153],"chemo;":[156],"60%":[157],"baseline":[159,222],"mets":[161],"(60/83":[162],"treated).":[163],"follow-up":[165],"30":[167],"wks.":[168],"In":[169],"response-evaluable":[171],"population":[172],"assessed":[173],"IRC":[175],"(122":[176],"measurable":[179,223],"at":[181],"baseline),":[182],"49.2%":[185],"(95%":[186,194,210,216,234],"CI":[187,195,211,217,235],"40.0\u201358.4;":[188],"all":[189],"PRs);":[190],"DCR":[191,213],"79.5%":[193],"71.3\u201386.3).":[196],"For":[197,219],"chemo":[201,312],"(n":[204,226],"=":[205,227],"96),":[206],"43.8%":[209],"33.6\u201354.3);":[212],"78.1%":[215],"68.5\u201385.9).":[218],"34),":[228],"IRC-assessed":[229],"55.9%":[233],"37.9\u201372.8),":[236],"including":[237,294],"five":[238],"CRs.":[239],"Updated":[240],"ORR,":[241],"DOR":[242],"PFS":[244],"data":[245],"will":[246],"be":[247],"presented.":[248],"Overall,":[249],"27.5%":[250],"grade":[254],"3\u20135":[255],"adverse":[256],"events":[257],"(AEs),":[258],"commonly":[260],"dyspnea":[261],"(3.6%)":[262],"pulmonary":[264],"embolism":[265],"(2.2%);":[266],"low":[267],"rates":[268],"dose":[270],"interruptions":[271],"(19.6%),":[272],"reductions":[273],"(8.7%),":[274],"withdrawals":[276],"(8.0%)":[277],"due":[278],"AEs":[280],"seen.":[282],"Conclusions:":[283],"Alectinib":[284],"well":[286],"tolerated":[287],"achieved":[289],"robust":[291],"treatment":[292],"response,":[293],"excellent":[295],"intracranial":[296],"activity,":[297],"crizotinib;":[306],"also":[309],"mets.":[316],"A":[317],"phase":[318],"3":[319],"trial":[320,334],"first-line":[322],"vs":[324],"an":[327],"expanded":[328],"access":[329],"program":[330],"are":[331],"ongoing.":[332],"Clinical":[333],"information:":[335],"NCT01801111.":[336]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":10},{"year":2015,"cited_by_count":11}],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2016-06-24T00:00:00"}